Key statistics
On Monday, Newron Pharmaceuticals SpA (0QOI:LSE) closed at 19.64, -38.34% below its 52-week high of 31.85, set on Jan 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 19.64 |
| Low | 19.64 |
| Bid | -- |
| Offer | -- |
| Previous close | 19.91 |
| Average volume | 9.09k |
|---|---|
| Shares outstanding | 20.01m |
| Free float | 17.24m |
| P/E (TTM) | 15.98 |
| Market cap | 397.40m CHF |
| EPS (TTM) | 1.24 CHF |
Data delayed at least 20 minutes, as of Feb 16 2026 17:26 GMT.
More ▼
- EQS-News: Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
- EQS-News: Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
- EQS-News: Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
- EQS-News: Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
- EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
- EQS-DD: Newron Pharmaceuticals S.p.A.: Luca Benatti, sell
- EQS-DD: Newron Pharmaceuticals S.p.A.: Luca Benatti, sell
More ▼
